CTOs on the Move

ChemDiv

www.chemdiv.com

 
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering discovery opportunities and services for life science partners, and merging industrial and academic efforts to bring new
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.chemdiv.com
  • 6605 Nancy Ridge Dr
    San Diego, CA USA 92121
  • Phone: 858.794.4860

Executives

Name Title Contact Details

Similar Companies

HealthScape

HealthScape is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Biosciences

Paragon Biosciences invests in and launches biopharmaceutical companies to develop novel therapies for severe medical conditions which do not yet have adequate treatments. Our mission is to help people live longer, healthier lives. Paragon advances that mission through its contribution of Bioscience Innovation Capital(TM): For rare and complex diseases, Paragon analyzes the viability of potential therapies, invests in new biopharmaceutical companies to further develop promising treatments, catalyzes the progress of its portfolio companies through early-incubation services, and provides clinical and regulatory guidance by a team with a near-perfect track record of first-cycle novel drug approvals.

BioVex Inc

BioVex Inc is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diazyme

Diazyme is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eyenovia

Eyenovia is a clinical stage, biopharmaceutical company transforming the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia`s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics.